Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized study of SentoClone in advanced malignant melanoma
2008-007515-33Phase 2Active
- Sponsor
- SentoClone International AB
- Start
- Apr 2009
- Modality
- Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of SentoClone in melanoma (2 arms), sponsored by SentoClone International AB. Primary endpoint: Tumour response rate (RECIST 1.1, IRC assessed). Started Apr 2009; status: active.
02
Drugs
SentoClone
03
Conditions
melanoma
Beyond the preview
Go deeper on 2008-007515-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-007515-33.